Roche new eye drug shines amid COVID products pulling down Q1 sales

April 27, 2023

in Stocks

Reading Time: 3 mins read

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) Q1 sales fell due to “significantly lower demand” for COVID-19 tests, however new eye drug Vabysmo helped temper the drop.

The Swiss pharma giant also confirmed its FY023 outlook.

Support authors and subscribe to content

This is premium stuff. Subscribe to read the entire article.

Gain access to all our Premium contents.
More than 100+ articles.

Subscribe Now

Buy Article

Unlock this article and gain permanent access to read it.

Unlock Now

Roche new eye drug shines amid COVID products pulling down Q1 sales

Related Articles

Trump’s Policies Could Cause Inflation Spike Americans Voted Against

Stock Market Outlook: 3 Main Risks to Trump Trade, Morgan Stanley Says

Dogecoin Is Worth More Than Ford After Postelection Crypto Boom

The Biggest Stock Market Risk After Trump Win Is China Trade War Move

Why David Einhorn Is Buying CNH, a Cheap Stock ‘No One Cares About’

5 Charts Showing the Immense Market Impact of Trump’s Presidential Win: BofA

Oil Outlook: US Production Boom, Weak China Demand to Lead to Oversupply in 2025

Stock Market Today: Tech Leads Sell-Off As Rate-Cut Odds Fall on Powell

Inflation Outlook: 4 Signs of Re-Inflation Investors Should Watch Out for

Navigate Site

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?

Roche new eye drug shines amid COVID products pulling down Q1 sales

Support authors and subscribe to content

Subscribe

Buy Article

Related Articles

Navigate Site

Follow Us

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?